FDA approved Victoza – the new anti diabetes drug

June 21, 2011

Victoza (liraglutide) is a new hypoglycemic preparation for adults who have diabetes, which is approved by FDA. It should be injected once a day in treatment of type 2 diabetes. This drug reduces blood glucose levels, which prevents and decreases the long term complications of the disease. But it should be taken only while keeping a diet or performing a course of special exercises along with other associated hypoglycemic preparations. The mechanism of Victoza lies in increasing the production of insulin after eating, it belongs to glucagon-like peptide-1 (GLP-1) receptor agonists.

Side effects

Statistics show that more than 1.5 million cases of diabetes patients are diagnosted anually, which are the reason of mortality and disorder. The most common side effect of Victoza is pancreatitis (inflammation of the pancreas). The clinical research which involved approximately 4.000 patients, demonstrated that patients who took Victoza got pancreatitis more often then those who took other hypoglycemic preparations. The patient shouldn't | take Victoza during the manifestation of symptoms, such as abdominal pain and nosia. The FDA warned that Victoza should be taken with prudence by those who had or are suffering from pancreatitis. Other side effects which were diagnosted during the research were the following: vomit, headache, diarrhea and hives.

The clinical research also shows that Victoza doesn't cause serious risk of cardiovascular disorder, such as strokes and heart attacks. Those results were received within the group of people with low susceptibility to cardiovascular diseases.

According to the FDA guideline, the side effects caused by Victoza are going to be studied more specifically in the groups of people with higher susceptibility to cardiovascular diseases.

Animal trials

Animal trials handled by FDA show that there is a risk of cancer tumors of thyroid gland, which showed up in mice and rats after a course of Victoza with doses eight times higher than those ment for people. There were no identical trials for people, thus the specialists cannot assure that there is no risk of thyroid tumors or a very rare type of thyroid cancer called medullary thyroid cancer in people taking Victoza. Also, pleople who already run a risk of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, a rare genetic condition, should not take this medicine. That is why this drug shouldn't be prescribed for diabetes treatment without deeper investigations in the field.

Victoza has both the risky side effects as well as a great potential to help people overcome and cope with diabetes. It's advantages prevail over the risks of pancreatitis and medullary thyroid cancer.